The breast journal
Ibrahim NK, Hortobagyi GN.
PMID: 21223440
Breast J. 1998 Jul;4(4):213-29. doi: 10.1046/j.1524-4741.1998.440213.x.
A comprehensive review of the literature from 1975 to 1995 was conducted. Reports were identified using the Cancerline and Medline databases. The chemical structure, estrogen agonist and antagonist activity, and in vitro studies were reviewed and compared with those...
Cite
Ibrahim NK, Hortobagyi GN. New antiestrogens in breast cancer: a review. Breast J. 1998;4(4):213-29doi: 10.1046/j.1524-4741.1998.440213.x.
Ibrahim, N. K., & Hortobagyi, G. N. (1998). New antiestrogens in breast cancer: a review. The breast journal, 4(4), 213-29. https://doi.org/10.1046/j.1524-4741.1998.440213.x
Ibrahim, N K, and Hortobagyi, G N. "New antiestrogens in breast cancer: a review." The breast journal vol. 4,4 (1998): 213-29. doi: https://doi.org/10.1046/j.1524-4741.1998.440213.x
Ibrahim NK, Hortobagyi GN. New antiestrogens in breast cancer: a review. Breast J. 1998 Jul;4(4):213-29. doi: 10.1046/j.1524-4741.1998.440213.x. PMID: 21223440.
Copy
Download .nbib
Trends in endocrinology and metabolism: TEM
Avioli LV.
PMID: 10481162
Trends Endocrinol Metab. 1999 Oct;10(8):317-319. doi: 10.1016/s1043-2760(99)00176-9.
Although estrogens have proved useful in the prevention and treatment of osteoporosis, their side effects (for example, those on breast and endometrial cancer) are worrying to patients and physicians alike. Therefore, selective estrogen receptor modulator (SERM) drugs have been...
Cite
Avioli LV. SERM Drugs for the Prevention of Osteoporosis. Trends Endocrinol Metab. 1999;10(8):317-319doi: 10.1016/s1043-2760(99)00176-9.
Avioli, L. V. (1999). SERM Drugs for the Prevention of Osteoporosis. Trends in endocrinology and metabolism: TEM, 10(8), 317-319. https://doi.org/10.1016/s1043-2760(99)00176-9
Avioli. "SERM Drugs for the Prevention of Osteoporosis." Trends in endocrinology and metabolism: TEM vol. 10,8 (1999): 317-319. doi: https://doi.org/10.1016/s1043-2760(99)00176-9
Avioli LV. SERM Drugs for the Prevention of Osteoporosis. Trends Endocrinol Metab. 1999 Oct;10(8):317-319. doi: 10.1016/s1043-2760(99)00176-9. PMID: 10481162.
Copy
Download .nbib
Expert opinion on emerging drugs
Cho CH, Nuttall ME.
PMID: 15989501
Expert Opin Emerg Drugs. 2001 Apr;6(1):137-54. doi: 10.1517/14728214.6.1.137.
Accelerated bone loss secondary to loss of ovarian function at menopause is well recognised as a major risk factor for osteoporotic fractures in postmenopausal women. Postmenopausal bone loss can be prevented or arrested by oestrogen replacement therapy (ERT). It...
Cite
Cho CH, Nuttall ME. Therapeutic potential of oestrogen receptor ligands in development for osteoporosis. Expert Opin Emerg Drugs. 2001;6(1):137-54doi: 10.1517/14728214.6.1.137.
Cho, C. H., & Nuttall, M. E. (2001). Therapeutic potential of oestrogen receptor ligands in development for osteoporosis. Expert opinion on emerging drugs, 6(1), 137-54. https://doi.org/10.1517/14728214.6.1.137
Cho, C H, and Nuttall, M E. "Therapeutic potential of oestrogen receptor ligands in development for osteoporosis." Expert opinion on emerging drugs vol. 6,1 (2001): 137-54. doi: https://doi.org/10.1517/14728214.6.1.137
Cho CH, Nuttall ME. Therapeutic potential of oestrogen receptor ligands in development for osteoporosis. Expert Opin Emerg Drugs. 2001 Apr;6(1):137-54. doi: 10.1517/14728214.6.1.137. PMID: 15989501.
Copy
Download .nbib
